ArticleActa pharmacologica Sinica2026
VsNsbench: evaluating AlphaFold3-embed induced-fit mechanism for enhanced virtual screening.
Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AI-Powered Marine Drug Discovery: A Putative Dual c-Met/VEGFR2 Lead Candidate for Hepatocellular Carcinoma via Deep Learning and Multiscale Simulation.Current issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While AlphaFold3 (AF3) extends AlphaFold2 (AF2) by predicting holo structures, it remains unclear whether its modeling process captures similar induced-fit mechanisms. In this study, we benchmarked the VS performance of ligand-induced AF3 holo structures on two datasets: a subset of DUD-E and VsNsBench designed to avoid sequence-level information leakage. On both datasets, AF3 holo structures demonstrated substantially improved enriching capability compared to AF3 apo, experimental apo, and AF2 structures. Compared to experimental holo structures, AF3 models demonstrated inferior performance on the DUD-E subset but performed slightly better on VsNsBench. Further analysis revealed that AF3's induced modeling critically depends on the bound ligand's affinity: high-affinity ligands produced conformations enabling excellent enrichment, while low-affinity or random ligands yielded poor performance. Moreover, direct VS using AF3 alone achieved satisfactory performance, but computational efficiency remains a major bottleneck for large-scale applications, even with single-round multiple sequence alignment (MSA) generation. In a DFG-motif kinase case study, AF3 successfully modeled inhibitor-specific conformations with a 75% success rate. These findings demonstrate that AF3 effectively incorporates induced-fit modeling, though improvement is needed, particularly for modeling multi-state conformational ensembles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.